A comparative study of the estrogenic potential of two synthetic @entity172 ( XXXX and @entity2082 ).

@entity1 @entity172 @entity39 @entity1184 @entity2082 @entity168 @entity3202 @entity8473 @entity18831 @entity2008 @entity2588
The purpose of this study was to establish the relative estrogenicity of @entity2082 and @entity8473 and to establish .05 and .1 mg of @entity8473 as standard reference preparations for the comparative study of other compounds. @entity1 were selected from a large group of primary @entity2588 , secondary @entity2588 , and postmenopausal @entity1 . All required hormonal replacement therapy. @entity1 with @entity2008 or those with diminished or abnormal response were excluded. Vaginal cytology was used as the main method for the assessment of the response. Before treatment all had either an @entity3202 pattern (Maturation Index = 50-50-0) or a @entity1184 pattern (MI=5-95-0) with a mean value of 10-87-3 for @entity1 with primary @entity2588 and 18-79-3 in the other 2 groups. @entity1 with a proliferative intermediate cell pattern and postmenopausal @entity1 thought to have continuing endogenous @entity172 activity were omitted. @entity2082 or @entity8473 were given orally in doses of .025, .05, and .1 mg for a period of 10 days during which frequent vaginal smears were made. When cell patterns showed extremely marked cytolysis of the glycogen-containing intermediate cells and a low percentage of karyopyknotic superficial cells these @entity1 were excluded. 40 @entity1 were finally included. The effects of @entity172 on the vaginal epithelium in all 40 @entity1 after 10 days therapy were quite uniform. In those cases showing delayed regression of estrogenic effects 4 mg of @entity18831 was given daily for 10 days. These @entity1 then showed a reduction in the superficial cell percentage accompanied by a shift to the left in the maturation index such as 0-40-60 before to 0-95-5 after treatment. A few @entity1 had an insignificant reduction in the superficial cell percentages. Changes in the percentages of the intermediate type of cells were not significant. The regression was considered to be complete when the smear contained mainly small intermediate cells and parabasal cells with numerous leukocytes and some @entity39 . Both @entity172 preparations produced the same vaginal response at .05 mg doses. Tablets of .05 and .1 mg @entity8473 were chosen for further study. The increase in the superficial cell index to 30 ( @entity168 plus or minus 18.5) following treatment with .05 mg and the increase to 54.1 ( @entity168 plus or minus 26.7) following .1 mg have been adopted as standard vaginal responses. The term estrogenic effect used in vaginal cytology is taken to mean the local vaginal effect induced by @entity172 .
